Clinical Trials Logo

Achromatopsia clinical trials

View clinical trials related to Achromatopsia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04124185 Completed - Achromatopsia Clinical Trials

Natural History Study for Achromatopsia

Start date: September 13, 2011
Phase:
Study type: Observational [Patient Registry]

In preparation for human clinical trials we intend to undertake a detailed phenotypic study to help to identify patients who may be suitable for therapeutic intervention. In addition, with the recent availability of advanced imaging modalities, further detailed phenotypic investigations will also be valuable in helping to probe the relationship between structure and function and may shed light on disease mechanisms.

NCT ID: NCT03758404 Completed - Achromatopsia Clinical Trials

Gene Therapy for Achromatopsia (CNGA3)

CNGA3
Start date: August 12, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical trial of adeno-associated virus vector (AAV) CNGA3 retinal gene therapy for patients with achromatopsia

NCT ID: NCT03278873 Completed - Achromatopsia Clinical Trials

Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3

Start date: June 29, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a longer-term follow-up study for patients who participated in one of the clinical trials: AAV - CNGB3 retinal gene therapy for patients with achromatopsia, or AAV - CNGA3 retinal gene therapy for patients with achromatopsia.

NCT ID: NCT03001310 Completed - Achromatopsia Clinical Trials

Gene Therapy for Achromatopsia (CNGB3)

CNGB3
Start date: January 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical trial of AAV - CNGB3 retinal gene therapy for patients with achromatopsia

NCT ID: NCT01846052 Completed - Achromatopsia Clinical Trials

Clinical and Genetic Characterization of Individuals With Achromatopsia

Start date: June 2013
Phase: N/A
Study type: Observational

The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.